1.1Nitrile at the R1 position
The linear C≡N group places a dipole along the attachment axis. Its terminal nitrogen provides a hydrogen-bond acceptor and remains uncharged near neutral pH.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The linear C≡N group places a dipole along the attachment axis. Its terminal nitrogen provides a hydrogen-bond acceptor and remains uncharged near neutral pH.
The –S(=O)₂CH₃ group presents two hydrogen-bond acceptor oxygens from a tetrahedral sulfur center. The methyl group occupies the remaining position on sulfur and provides a small nonpolar surface.
A –CH₂–CH₂–CH₂– tether closes a five-membered carbocycle with the two adjacent scaffold atoms. Ring closure constrains the geometry at both sites and presents a nonpolar surface.
A –C≡C– unit connects X and A through two sp-hybridized carbons. The triple bond places the two attachment vectors on a common axis and fixes their separation.
The three-membered carbon ring occupies a compact volume next to nitrogen. Its two remaining carbons have a fixed relationship to the attachment carbon because they form part of the same ring.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
An aryl sulfonamide replaces the aryl carboxamide at R4, and R5 is hydrogen. The pendant group attaches through the sequence aryl–SO₂–NH–CH₂–cyclopropyl, with the aryl carbon bonded directly to sulfur. Coupling the corresponding R4 arylsulfonyl chloride with cyclopropylmethylamine forms the sulfonamide.
A 384-well plate holds 8,000 receptor-expressing cells per well in a final assay volume of 40 microliters. An eight-point, threefold dilution series starts at 10 micromolar, with three wells per concentration and a matched vehicle concentration throughout. A fluorescence reader records 10 seconds of baseline and 90 seconds after addition, and the peak baseline-corrected signal enters a four-parameter concentration response fit.
Three parallel perfusion chambers contain the same serotonin receptor-expressing cell line and receive a 30-second pulse of one indoline derivative at its measured half-maximal concentration. The chambers receive fresh buffer for 2, 5, or 15 minutes before a second 30-second pulse at the same concentration. The ratio of the second peak calcium signal to the first gives the response recovery at each wash interval.
A microfluidic perfusion cartridge contains parallel chambers for a serotonin receptor-expressing cell line and its parental line. A switching valve delivers assay buffer, indoline solution, and wash buffer to both chambers while a fluorescence microscope records intracellular calcium. A fraction collector captures the outlet stream from each chamber separately for liquid chromatography and mass spectrometry, which measures indoline recovery during each pulse and wash.
A liquid handler prepares dilution series from an indoline stock plate and dispenses them into assay plates with vehicle and serotonin controls. Software imports the plate map and fluorescence traces, subtracts each well's baseline, and fits peak responses to a four-parameter logistic model. When the fitted midpoint falls between tested concentrations and its 95 percent confidence interval spans more than tenfold, the software schedules a repeat with closer concentration spacing around the midpoint.
Rb is an ethyl group bonded to nitrogen through its methylene carbon. The terminal methyl group extends one carbon beyond that attachment point.
A is a cyclobutyl group joined to L through one ring carbon. The four saturated carbons form a puckered ring that provides a compact nonpolar terminal group.
A is a phenyl group with fluorine at position 3 and methoxy at position 4, counted from its attachment to L. The methoxy oxygen provides a hydrogen-bond acceptor, and the fluorine occupies the adjacent ring position.
R60 and R61 form a –CH₂–CH₂–O–CH₂–CH₂– bridge whose two ends bond to the same nitrogen. The resulting six-membered ring places the ether oxygen opposite the nitrogen.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
or a pharmaceutically acceptable salt thereof, wherein Each Rx is independently H, halo, OR, C1-C6 alkyl, (CR2)0-1CN, OR, C(O)OR10, C3-C10 cycloalkyl, NR6C(O)R10, NR6SO2R8, or NH2, said alkyl and cycloalkyl are optionally substituted with 1 to 3 substituents selected from halo, OR and C1-C6 alkyl; Each R is independently H, C1-C6 alkyl or C3-C10 cycloalkyl, said alkyl and cycloalkyl are optionally substituted with 1 to 4 halo substituents;A · US 2014/0336224 A1 · ¶
R2 is selected from the group consisting of cyano; halo;B · US 2016/0067245 A1 · ¶
R4 is 1) H, 2) —NR6S(O)2R8, 3) (CR2)v—S(O)pR8, 4) C1-C6 alkyl, 5) C3-C6 cycloalkyl, 6) —(CH2)0-1-CN, 7) halo, 8) —C(O)OR8, 9) —NH2, 10) —NO2, 11) —OR, 12) —(CRa2)t-S(O)2R8, 13) —NR6C(O)R10, 14) —NR6C(O)OR10, 15) aryl, 16) heterocyclyl, or 17) heteroaryl; where said alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally substituted with one to three OR, C1-C6 alkyl or halo substituents;A · US 2014/0336224 A1 · claim 1
C1-3alkyl substituted with one or more independently selected halo substituents; unsubstituted phenyl; unsubstituted benzyl; benzyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C1-3alkyl, C1-3alkyloxy, C1-3alkyloxyC1-3alkyl, hydroxyC1-3alkyl, cyano, hydroxyl, amino, C(═O)R′, C(═O)OR′, C(═O)NR′R″, mono- or di(C1-3alkyl)amino, morpholinyl, (C3-7cycloalkyl)C1-3alkyloxy, trifluoromethyl and trifluoromethoxy, wherein R′ and R″ aB · US 2016/0067245 A1 · ¶
R1 is 1) H, 2) CN, 3) OR, 4) C1-C6 alkyl, 5) C3-C6 cycloalkyl 6) aryl, 7) heteroaryl, 8) heterocyclyl, 9) C(O)R10, 10) C(O)NRR6, or 11)C(O)OR10; wherein said alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl are optionally substituted with one to three CF3, OR, CN, C1-C6 alkyl, or halo substituents;A · US 2014/0336224 A1 · claim 1
C1-3alkyl substituted with one or more independently selected halo substituents; unsubstituted C3-7cycloalkyl;B · US 2016/0067245 A1 · ¶
C3-7cycloalkyl substituted with 1 or 2 substituents independently selected from C1-3alkyl, C1-3alkyl substituted with one or more independently selected halo substituents or hydroxyl; unsubstituted phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C1-3alkyl, hydroxyC1-3alkyl, C1-3alkyl substituted with one or more independently selected halo substituents, cyano, hydroxyl, C1-3alkyloxy-C1-3alkyl, C1-3alkyloxy, andB · US 2016/0067245 A1 · ¶
Each R9 is independently halo, CN, OCF3, C1-C6 alkyl, OR, NH2, aryl or heteroaryl, where said alkyl, aryl or heteoraryl may be optionally substituted with one to three CN, OCF3, OR, C1-C6 alkyl, NH2 or halo substituents;A · US 2014/0336224 A1 · claim 1
wherein each W1d, W1e, W2e and W1f is independently selected from CH and N; each R7d, R7e, R7f, R7g, R8d, R8e, R8f, R8g is independently selected from hydrogen, methyl and fluoro; or each CR7dR8d, CR7eR8e, CR7fR8f, CR7gR8g form a carbonyl group; each R9d, R9e, R9f, and R9g is fluoro; each q1, q2, q3 or q4 is independently selected from 0, 1 and 2; r is 0 or 1; s is 0 or 1; each R3b and R3c is selected from the group consisting of C1-3alkyl;B · US 2016/0067245 A1 · ¶
The notation “C1-3alkyl substituted with one or more independently selected halo substituents” as used herein alone or as part of another group, defines an alkyl group as defined above, substituted with 1, 2, 3 or more halogen atoms, such as fluoromethyl; difluoromethyl; trifluoromethyl; 2,2,2-trifluoroethyl; 1,1-difluoroethyl; 3,3,3-trifluoropropyl.B · US 2016/0067245 A1 · ¶ 48
An empty cell means only that no passage was reproduced there.
Despite significant therapeutic advances in the treatment of hypertension and heart failure, the current standard of care is suboptimal and there is a clear unmet medical need for additional therapeutic/pharmacological interventions.A · US 2014/0336224 A1 · ¶ 7
This invention addresses those needs by providing compounds and compositions which may be useful for the treatment or prevention of hypertension, heart failure, other cardiovascular disorders and other aldosterone disorders.A · US 2014/0336224 A1 · ¶ 7
The present invention relates to novel triazolo[4,3-a]pyridine derivatives which are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”) and which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved.B · US 2016/0067245 A1 · ¶ 2
Furthermore, glutamate is at the centre of several different neurological and psychiatric diseases, where there is an imbalance in glutamatergic neurotransmission.B · US 2016/0067245 A1 · ¶ 3
patent.fyi, US 2026/0356814 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356814/, SHA-256 395af1b98f5345854a7caed092b3f09025cf6738a566473ac1dc3337d429f13c